Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
We bring the federal record — legislation, regulations, lobbying, SEC filings, enforcement, and the courts — into one entity graph, and answer your questions with a citation behind every claim.
A real dossier on Eli Lilly, generated 2026-07-02 from the held federal corpus — 70 primary sources, every claim numbered, machine-verified against the evidence. Nothing staged; open any citation and land on the government publisher’s own page.
Each workflow is the same contract: a small input, a finished cited work product, an honest wall-clock. Every row links to a real finished example — never an empty form.
Any company, as a sourced narrative across bills, regs, lobbying, SEC filings, enforcement, and the courts — every claim cited.
One company or organization — the name as it appears in filings (“Eli Lilly”, “Goldman Sachs”).
A structured, citation-anchored dossier with per-surface coverage badges and a verification appendix. See one →
A watchlist in, a ranked and cited brief out — the latest activity across every corpus, with what matters surfaced first.
Sources are messy and disagree. We reconcile them so one name means one thing — in every corpus. The figure is that sentence, drawn to scale: one company’s node in the graph and every record set it resolves into, from the demo dossier’s real counts. Every source is commercial-use-cleared.
Eli Lilly — 773 records, one graph
If you can’t show your work, you can’t use the answer.
Claims carry citations to primary government records; fabricated reference numbers are caught deterministically, and an audit pass checks the most load-bearing claims verbatim against the evidence.
A canonical graph makes a company or official the same node across every corpus, so one name means one thing.
Verify any claim in one click against its publisher. Every source is screened for commercial use, with an auditable trail.
Reg-affairs & government-relations teams in healthcare, finance, and AI.
Trade groups tracking every issue that defines their members' world.
Firms that win by surfacing the catalyst first.
Buy-side & M&A teams pricing policy exposure into the deal.
Open six finished, fully-cited artifacts in the demo — then tell us what you cover and we’ll set your team up to run it live.
Eli Lilly is a top-tier federal policy actor: 300 lobbying filings on record across 12+ retained firms, sustained in-house spend running $1.4–1.8M per quarter, and a $65B revenue / $21B net income financial profile that makes it one of the most consequential pharmaceutical companies before Congress and regulators. Its sharpest immediate exposure is a triple FDA warning letter cluster issued September 2025, all directed to CEO David Ricks personally, concerning promotional violations for tirzepatide (Zepbound/Mounjaro) — its highest-growth franchise and the center of gravity for its current market capitalization.
Up to 5 companies or issues, comma-separated — names as they appear in filings work best (“Pfizer, UnitedHealth, drug pricing”).
A ranked, dated feed plus a synthesized memo — every item cited to its primary source. See one →
The matrix compares real, graph-linked record counts across every surface — this is the actual grid from the demo, four companies wide. Behind each cell: a cited sample of the records it counts.
| Lobbying | SEC | Bills | Rules | Enforcement | Exclusions | FARA | |
|---|---|---|---|---|---|---|---|
| Eli Lilly | 313 | 306 | 1 | 8 | 3 | — | 0 |
| Pfizer | 563 | 519 | 0 | 24 | — | — | 0 |
| UnitedHealth | 318 | 261 | 0 | 0 | 1 | — | 0 |
| Goldman Sachs | 233 | 453 | 20 | 2 | 1 | — | 0 |